Madam Speaker, the short answer is because we were not sure, especially in the early days when we were purchasing these vaccines, which ones would be successful. On top of that, we do not know if a particular vaccine is going to be indicated for use in a particular population.
Early on, we knew we would need guidance as a federal government to place our bets, if you will, on promising vaccines. That is why we struck the vaccine task force. It is composed of experts in virology, pharmaceutical companies and vaccine development, and they have ably advised us in the diversity of our portfolio, which situates Canada in a very ideal spot.